Список литературы

Поставить закладку

EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failureq. European Association for the Study of the Liver. Journal of Hepatology 2017; 66: 1047–1081.
Hernaez R., Solà E., Moreau R., Ginès P. Acute-on-chronic liver failure: an update. Gut 2017; 66: 541–553.
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases //Journal of Hepatology. – 2014. - Vol. 61. – P. 642–659.
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver //Journal of Hepatology. – 2010. – Vol. 53. – P. 397–417.
Kim W.R., Biggins S.W., Kremers W.K. et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018–1026.
Krowka M.J. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med. 2005; 26: 587–597.
Rai R., Nagral S., Nagraly A. Surgery in a Patient with Liver Disease. J Clin Exp Hepatol 2012; 2: 238–246.
Møller S., Henriksen J.H. Cirrhotic cardiomyopathy. J Hepatol. 2010; 53: 179–190.
Ruiz-del-Árbol L., Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol 2015; 21(41): 11502-11521.
Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology 2007;46:2032–2039.
Gual A, Segura L, Contel M, Heather N, Colom J. AUDIT-3 and AUDIT-4: effectiveness of two short forms of the alcohol use disorders identification test. Alcohol Alcohol 2002;37:591– 596.
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. European Association for the Study of the Liver// Journal of Hepatology. – 2012. - Vol. 57. – P. 399-420.
Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243: 373–379.
Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006; 12: 966–71.
Jalan R., Pavesi M., Saliba F., Amoros A., Fernandez J., Holland-Fischer P. et al. The CLIF Consortium acute decompensation score (CLIF-C ADs) for prognosis of hospitalized cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015;62:831–840.
Li N., Huang C., Yu K., Lu Q., Shi G., Zheng J. Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure. The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF. Medicine 2017; 96 (17): 6802.
Stoelting R.K., Dierdorf S.F. Anesthesia and Co-existing Disease, 4rd ed. Elsevier Health Sciences. 2002. - 798 р.
Fabian J.A. Anesthesia for Organ Transplantation. - Philadelphia: GB Lippincott, 1992. - 194 p.
Arroyo V., Moreau R., Jalan R., Ginès P. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. Journal of Hepatology 2015; vol. 62: S131–S143.
Soubhia A.F., Lauz S., Montero E.F., Menezes A, Mespaque LB, Facin E. Effects of the inhalational anesthetics halothane and sevoflurane on an experimental model of hepatic injury.Rev Bras Anestesiol. 2011 Sep-Oct;61(5):591-603, 324-30
Chondrogiannis K, Hadziyannis E, Fassoulaki A.Propofol or sevoflurane anaesthesia does not affect hepatic integrity as assessed by the M30 & M65 cell death markers & liver enzymes. Indian J Med Res. 2014 Nov;140(5):630-6.
Fujita Y, Kimura K, Hamada H, Takaori M.Comparative effects of halothane, isoflurane, and sevoflurane on the liver with hepatic artery ligation in the beagle. Anesthesiology. 1991 Aug;75(2):313-8
Abou Hussein M, Mahmoud F, Beltagy R, Hasanin A, Yassen K, Attar A. Desflurane compared to sevoflurane for cirrhotic patients undergoing major liver resection. A randomized control study. Middle East J Anaesthesiol. 2015 Jun;23(2):213-23.
Suttner SW, Schmidt CC, Boldt J, Hüttner I, Kumle B, Piper SN.Low-flow desflurane and sevoflurane anesthesia minimally affect hepatic integrity and function in elderly patients. Anesth Analg. 2000 Jul;91(1):206-12
Soubhia AF, Lauz S, Montero EF, Menezes A, Mespaque LB, Facin E.Effects of the inhalational anesthetics halothane and sevoflurane on an experimental model of hepatic injury. Rev Bras Anestesiol. 2011 Sep-Oct;61(5):591-603, 324-30.
Murray J.M., Rowlands B.J., Trinick T.R.: Indocyanine green clearance and hepatic function during and after prolonged anaesthesia: Comparison of halothane with isoflurane. Br J Anaesth 1992; 68:168-171.
Gatacel C., Losser M.R., Payen D.: The postoperative effects of halothane versus isoflurane on hepatic artery and portal vein blood flow in humans. Anesth Analg 2003; 96:740-745.
Gelman S.: General anesthesia and hepatic circulation. Can J Physiol Pharmacol 1987; 65:1762-1779.
Frink E.J., Morgan S.E., Coetzee A., et al: The effects of sevoflurane, halothane, enflurane, and isoflurane on hepatic blood flow and oxygenation in chronically instrumented greyhound dogs. Anesthesiology 1992; 76:85-90.
Armbruster K., Noldge-Schomburg G., Dressler I.M.J, et al: The effects of desflurane on splanchnic hemodynamics and oxygenation in the anesthetized pig. Anesth Analg 1997; 84:271277.
Hartman J.C., Pagel P.S., Proctor L.T., et al: Influence of desflurane, isoflurane and halothane on regional tissue perfusion in dogs. Can J Anaesth 1992; 39:877-887.
Aneman A., Pontén J., Fändriks L., et al: Splanchnic and renal sympathetic activity in relation to hemodynamics during isoflurane administration in pigs. Anesth Analg 1995; 80:135-142.
Saxena R., Zucker S.D., Crawford J.M.: Anatomy and physiology of the liver. In: Zakim D, Boyer D, ed. Hepatology: A Textbook of Liver Disease, Philadelphia: WB Saunders; 2003:3-30.
Matsumoto N., Kotzumi M., Sugai M.: Hepatolobectomy-induced depression of hepatic circulation and metabolism in the dog is counteracted by isoflurane, but not by halothane. Acta Anaesthesiol Scand 1999; 43:850-854.
Crawford M.W., Lerman J., Saldivia V., et al: The effect of adenosine-induced hypotension on systemic and splanchnic hemodynamics during halothane or sevoflurane anesthesia in the rat. Anesthesiology 1994; 80:159-167.
Grundmann U., Zizzis A., Bauer C., Bauer M.: In vivo effects of halothane, enflurane, and isoflurane on hepatic sinusoidal microcirculation. Acta Anaesthiol Scand 1997; 41:760-765.
Crawford M.W., Lerman J., Saldivia V., et al: Hemodynamic and organ blood flow responses to halothane and sevoflurane anesthesia during spontaneous ventilation. Anesth Analg 1992; 75:1000-1006.
Conzen P.F., Vollmar B., Habazettl H., et al: Systemic and regional hemodynamics of isoflurane and sevoflurane in rats. Anesth Analg 1992; 74:79-88.
Bito H., Ikeda K.: Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth Analg 1996; 82:173-176.
Ebert T.J., Messana L.D., Uhrich T.D., et al: Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg 1998; 86:662-667.
Jones R.M., Koblin D.D., Cashman J.N., et al: Biotransformation and hepato-renal function in volunteers after exposure to desflurane (I-653). Br J Anaesth 1990; 64:482-487.
Nishiyama T., Yokoyama T., Hanaoka K.: Effects of sevoflurane and isoflurane anesthesia on arterial ketone body ratio and liver function. Acta Anaesthesiol Scand 1999; 43:347-351.
Obata R., Bito H., Ohmura M., et al: The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesth Analg 2000; 91:1262-1268.
Kim J.W., Kim J.D., Yu S.B., Ryu S.J. Comparison of hepatic and renal function between inhalation anesthesia with sevoflurane and remifentanil and total intravenous anesthesia with propofol and remifentanil for thyroidectomy.Korean J Anesthesiol. 2013 Feb;64(2):112-6
Rothenberg D.M., Connor C.J, Tuman K.J. Анестезия и гепатобилиарная система. В кн: Анестезия Рональда Миллера/под редакцией Р. Миллера. Пер. с англ. под общей ред. К.М. Лебединского: в 4 т. – СПб.: Человек, 2015.
Zaleski L., Abello D., Gold M.I.: Desflurane versus isoflurane in patients with chronic hepatic and renal disease. Anesth Analg 1993; 76:353-356.
Ko J.S., Gwak M.S., Choi S.J., Yang M., Kim M.J., Lee J.Y., Kim G.S., Kwon C.H., Joh J.W. The effects of desflurane and sevoflurane on hepatic and renal functions after right hepatectomy in living donors Transpl Int. 2010.
Debaene B., Goldfarb G., Braillon A., et al: Effects of ketamine, halothane, enflurane, and isoflurane on systemic and splanchnic hemodynamics in normovolemic and hypovolemic cirrhotic rats. Anesthesiology 1990; 73:118-124.
Tsai H, Lin Y, Ko C, et al. Propofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a meta-analysis of randomized controlled trials. PLoS One 2015; 10:e0117585.
Watanabe K, Hikichi T, Takagi T, Suzuki R, Nakamura J, Sugimoto M, Kikuchi H, Konno N, Takasumi M, Sato Y, Hashimoto M, Irie H, Obara K, Ohira H. Propofol is a more effective and safer sedative agent than midazolam in endoscopic injection sclerotherapy for esophageal varices in patients with liver cirrhosis: a randomized controlled trial. Fukushima J Med Sci. 2018 Dec 8;64(3):133-141. doi: 10.5387/fms.2018-21. Epub 2018 Oct 21.
Wu J, Huang S, Chen Q, et al. The Influence of the severity of chronic virus related liver disease on propofol requirements during propofol-remifentanil Anesthesia. Yonsei Med J 2013; 54:231–237.
Yoshida H., Kudo T., Sawada M., Saito J., Tonosaki M., Hirota K. Effects of propofol and ketamine on postoperative hepatic and renal function: comparison between fentanyl and remifentanil as an adjuvant.Masui. 2012 Aug;61(8):794-9.
Ye L., Luo C.Z., McCluskey S.A., Pang Q.Y., Zhu T. Propofol attenuates hepatic ischemia/reperfusion injury in an in vivo rabbit model.J Surg Res. 2012 Dec;178(2):e65-70.
Servin F., Cockshott I.D., Farinotti R., et al: Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990; 65:177-183.
Thomson I.A., Fitch W., Campbell D., et al: Effects of ketamine on liver blood flow and hepatic oxygen consumption: Studies in the anaesthetized greyhound. Acta Anaesthesiol Scand 1988; 32:10-14.
González Gil A., Silván G., Illera J.C. Effects of barbiturate administration on hepatic and renal biochemical parameters in new zealand white rabbits. Contemp Top Lab Anim Sci. 2005 Nov;44(6):43-5.
Pandele G., Chaux F., Salvadori C., et al: Thiopental pharmacokinetics in patients with cirrhosis. Anesthesiology 1983; 59:123-126.
Couderc E., Ferrier C., Harberer J.P., et al: Thiopentone pharmacokinetics in patients with chronic alcoholism. Br J Anaesth 1984; 56:1393-1396.
Kalkan Y., Tomak Y., Altuner D., Tumkaya L., Bostan H., Yilmaz A., Unal D., Kara A., Turan A.Hepatic effects of ketamine administration for 2 weeks in rats.Hum Exp Toxicol. 2013
Duvaldestin P., Chauvin M., Lebrault C., et al: Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital. Acta Anaesthesiol Scand 1991; 35:159-163.
Trouvin J.H., Farinotti R., Haberer J.P., et al: Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth 1988; 60:762-767.
Baughman V.L., Cunningham F.E., Layden T.: Pharmacokinetic/pharmacodynamic effects of dexmedetomidine in patients with hepatic failure. Anesth Analg 2000; 90(Suppl):S391.
Tegeder I., Lötsch J., Geisslinger G.: Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37:17-40.
Haberer J.P., Schoeffler P., Couderc E., et al: Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54:1267-1270.
Raucoules-Aimé M., Kaidomar M., Levron J.C., et al: Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. Anesth Analg 1997; 84:10191024.
Dershwitz M., Hoke J.F., Rosow C.E., et al: Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996; 84:812-820.
Dumont L., Picard V., Marti R.A., et al: Use of remifentanil in a patient with chronic hepatic failure. Br J Anaesth 1998; 81:265-267.
Tanaka N., Nagata N., Hamakawa T., Takasaki M.: The effect of dopamine on hepatic blood flow in patients undergoing epidural anesthesia. Anesth Analg 1997; 85:286-290.
Darling J.R., Murray J.M., Hainsworth A.M., et al: The effect of isoflurane or spinal anesthesia on indocyanine green disappearance rate in the elderly. Anesth Analg 1994; 78:706-709.
Vagts D.A., Iber T., Puccini M., et al: The effects of thoracic epidural anesthesia on hepatic perfusion and oxygenation in healthy pigs during general anesthesia and surgical stress. Anesth Analg 2003; 97:1824-1832.
Kennedy Jr.W.F., Everett G.B., Cobb L.A., et al: Simultaneous systemic and hepatic hemodynamic measurements during high spinal anesthesia in normal man. Anesth Analg 1970; 49:1016-1024.
Greitz T., Andreen M., Irestedt L.: Haemodynamic and oxygen consumption in the dog during high epidural block with special reference to the splanchnic region. Acta Anaesthesiol Scand 1983; 27:211-217.
Bion JF1, Bowden MI, Chow B, Honisberger L, Weatherley BC.Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med. 1993;19 Suppl 2:S94-8.
Chow B1, Bowden MI, Ho E, Weatherley BC, Bion JF.Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. Br J Anaesth. 2000 Dec;85(6):850-5.
De Wolf AM1, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR.Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth. 1996 May;76(5):624-8.
Kiamanesh D, Rumley J, Moitra V. Monitoring and managing hepatic disease in anesthesia. Brit J Anaesth 2013; 111:i50–i61.
Cammu G., Bossuyt G., De Baerdemaeker L., et al: Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation. J Clin Anesth 2002; 14:135-139.
Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwan 2014; 52:54–58.
Head-Rapson A.G., Devlin J.C., Parker J.C.: Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 1994; 73:613-618.
Thomas S.D., Boyd A.H.: Prolonged neuromuscular block associated with acute fatty liver of pregnancy and reduced plasma cholinesterase. Eur J Anaesthesiol 1994; 11:245-249.
Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis 2004;19:281–312.
Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010;7:515–525.
Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci 2008;53:529–538.
Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:307–312.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–1081.
Cao Q, Yu CB, Yang SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17(1):9-16. doi:10.1016/j.hbpd.2018.01.005
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351–1360.
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046.
Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993;38:916–922.
Jiang Q., Xue-Hua J., Ming-Hua Z. L-ornithine-Laspartate in the management of hepatic encephalopathy: meta-analysis. J Gastroenterol Hepatol 2009; 24(1): 9-14.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DG. A randomized trial of polyethylene glycol 3350-electrolyte solution (PEG) and lactulose for patients hospitalized with acute hepatic encephalopathy. Hepatology 2012;56:915A–916A, (abstr. 1546).
Higuera-de-la-Tijera F, Servнn-Caamaсo AI, Salas-Gordillo F, et al. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Can J Gastroenterol Hepatol. 2018;2018:3015891. Published 2018 Jul 10. doi:10.1155/2018/3015891
Runyon BAPractice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841–855.
Rimola A, Gracia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142–153.
Benmassaoud A, Freeman SC, Roccarina D, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD013123. Published 2020 Jan 16. doi:10.1002/14651858.CD013123.pub2
Sola-Vera J, Miсana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37: 1147–1153.
Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26: 46–54.
Rimola A, Salmerуn JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995;21:674–679.
Terg R, Cobas S, Fassio E, Landeira G, Rнos B, Vasen W, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000;33:564–569.
Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23: 75–84.
Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923–930.
Fabrizi F, Dixit V, Martin P. Metaanalysis: terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935–944.
Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360–1368.
Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576–584.
Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9(9):CD013103. Published 2019 Sep 12. doi:10.1002/14651858.CD013103.pub2 106.
Nanda A, Reddy R, Safraz H, Salameh H, Singal AK. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018;52(4):360-367. doi:10.1097/MCG.0000000000000913
Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(16):e0431. doi:10.1097/MD.0000000000010431
Abid S. et al. Terlipressin vs Octreotide in bleeding esophageal varicel as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. The American Journal of Gastroenterology 2009; 104: 21-29.
Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD002147.
Kumar M, Ahmad J, Maiwall R, et al. Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial. Hepatology. 2020;71(1):235-246. doi:10.1002/hep.30794
Kovalic AJ, Majeed CN, Samji NS, Thuluvath PJ, Satapathy SK. Systematic review with metaanalysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis. Aliment Pharmacol Ther. 2020;52(8):1298-1310. doi:10.1111/apt.16078
Miao Z, Lu J, Yan J, Lu L, Ye B, Gu M. Comparison of Therapies for Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhosis: A Network Meta-analysis of Randomized Controlled Trials. Clin Ther. 2020;42(7):1246-1275.e3. doi:10.1016/j.clinthera.2020.04.014
Sharma M, Singh S, Desai V, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology. 2019;69(4):1657-1675. doi:10.1002/hep.30220
Ahluwalia V., Wade J.B., Thacker L. et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013; 59:467–473.
Alshamsi F, Alshammari K, Belley-Cote E, et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2020;46(1):1-16. doi:10.1007/s00134-019-05783-y
Steiner C., Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry // Liver. – 2002. – Vol.22. – №2. – P. 20 – 25.
Hassanein T.I., Tofteng F., Brown R.S. et al. Randomized Controlled Study of Extracorporeal Albumin Dialysis for Hepatic Encephalopathy in Advanced Cirrhosis. Hepatology 2007; 46: 1853-1862.
Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, Samuel D. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med. 2013; 159(8): 522-31.
Banares R., Nevens F., Larsen F.S. et al. Extracorporeal Albumin Dialysis With the Molecular Adsorbent Recirculating System in Acute-on-Chronic Liver Failure: The RELIEF Trial. Hepatology 2013; 57: 1153-1162.
Gerth HU, Pohlen M, ThoÈlking G, PavenstaÈdt H, Brand M, Wilms C. et al. Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: Results from a case-control study. PLoS ONE 2017; 12(4): e0175529.
Gerth H.U., Pohlen M., Brand M. et al. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure—A Retrospective Analysis. Crit Care Med 2017; 45: 1616–1624.
Zheng Z., Li X., Li Z., Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression Experimental and therapeutic medicine 2013; 6: 929-936.
Shen Yi, Wang Xu-Lin, Wang Bin et al. Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure A Time Series-Based Meta-Analysis. Medicine 2016; 95(3): e2506.
Larsen F.S., Schmidt L.E., Wendon J. et al. Liver assisting with high-volume plasma exchange in patients with acute liver failure // Hepatol. – 2010. – Vol.52. – P. 376A.
Larsen F.S., Schmidt L.E., Bernsmeier C., Rasmussen A., Isoniemi H., Patel V.C., Triantafyllou E., Bernal W., Auzinger G., Shawcross D., Eefsen M., Bjerring P., Clemmesen J.O., Hockerstedt K., Frederiksen H.J., Hansen B., Antoniades C.G., Wendon J. High-volume plasma exchange in patients with acute liver failure: An open randomized controlled trial. J Hepatol. 2016; 64(1): 69-78.
Lee J.Y., Kim S.B., Chang J.W., Park S.K., Kwon S.W., Song K.W., Hwang S., Lee S.G. Comparison of the molecular adsorbent recirculating system and plasmapheresis for patients with graft dysfunction after liver transplantation. Transplant Proc. 2010; 42(7): 2625-2530.
Yue-Meng Wan., Yu-Hua Li., Zhi-Yuan Xu., Jing Yang., Li-Hong Yang., Ying Xu., Jin-Hui Yang Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: A prospective study. Clin Apher. 2017; 1–9.
Ocskay K, Kanjo A, Gede N, et al. Uncertainty in the impact of liver support systems in acuteon-chronic liver failure: a systematic review and network meta-analysis. Ann Intensive Care. 2021;11(1):10. Published 2021 Jan 18. doi:10.1186/s13613-020-00795-0
Adani G.L., Lorenzin D., Currò G., Sainz-Barriga M., Comuzzi C., Bresadola V., Avellini C., Baccarani U. Selective Bilirubin Removal by Plasma Treatment With Plasorba BR-350 for Early Cholestatic Graft Dysfunction. Transplantation Proceedings. 2007; 39: 1904–1906.
Фомин А.М., Лобаков А.И., Титова Г.В., Захаров Ю.И. Оценка эффективности плазмосорбции (Liver Support) при печеночной недостаточности у больных с механической желтухой. Альманах клинической медицины. 2015; 40: 101–108.
Li M., Wang Z., Wang Y. Part of plasmapheresis with plasma filtration adsorptioncombined with continuous hemodiafiltration inthe treatment of severe acute liver failure. Experimental and therapeutic medicine 2016; 12: 2582-2584.
Соколов А.А., Захаров М.В., Бельских А.Н. Возможности селективной плазмофильтрации при заболеваниях печени. Эфферентная терапия 2013; 9(1): 103-104.
Владимиров А.Г., Кукес В.Г., Андреев Д.А. Состояние системы цитохрома P-450 у больных острым инфарктом миокарда. Кардиоваскулярная терапия и профилактика, 2008; 7(4)
Alraish et al. Pharmacokinetics of tigecycline in critically ill patients with liver failure defned by maximal liver function capacity test (LiMAx). Ann. Intensive Care (2020) 10:106.
Bernal, W., Williams, R. Beyond KCH selection and options in acute liver failure. Hepatol Int 12, 204-213 (2018).